Stock Market & Financial Investment News

News Breaks March 18, 2013 08:05 EDT ALNY Alnylam initiates phase I study for subcutaneously delivered RNAi therapeutic Alnylam Pharmaceuticals announced that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin for the treatment of TTR-mediated amyloidosis. The Phase I trial of ALN-TTRsc is being conducted in the U.K. as a randomized, double-blind, placebo-controlled, single- and multi-dose, dose-escalation study, enrolling up to 40 healthy volunteer subjects. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of subcutaneously administered ALN-TTRsc. Secondary objectives include assessment of clinical activity of the drug as measured by serum TTR levels. Alnylam expects to present data from this trial in mid-2013. Upon completion of the Phase I trial, the company plans to start a Phase II clinical study of ALN-TTRsc in FAC patients by the end of 2013 and, assuming positive results, expects to start a pivotal trial for ALN-TTRsc in FAC patients in 2014. News For ALNY From The Last 14 Days Check below for free stories on ALNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 08:04 EDT ALNY Alnylam announces proof-of-concept data from RNAi program Subscribe for More Information May 16, 2013 07:29 EDT ALNY Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. May 14, 2013 08:43 EDT ALNY Alnylam has multiple upcoming positive catalysts, says JMP Securities JMP Securities believes that Alnylam will have multiple positive data catalysts over the next two months. The firm thinks that upcoming data and presentations will enhance the company's positioning and perception of its pipeline, and it keeps an Outperform rating on the shares. May 6, 2013 16:04 EDT ALNY Alnylam sees ending 2013 with over $320M in cash, equivalents Subscribe for More Information 16:03 EDT ALNY Alnylam reports Q1 EPS (15c), consensus (29c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.